Announcement Regarding AMED Grant Award for rogocekib (CTX-712)
Filed with TSE · · 2 pages · English
Chordia Therapeutics Inc. on 6ix
Earlier from Chordia Therapeutics
- Announcement Regarding Completion of Patient Enrollment in the Initial Expansion Cohort of rogocekib
- Announcement of Orphan Drug Designation in Japan for rogocekib for Relapsed or Refractory AML
- Announcement Regarding the Review Status of Orphan Drug Designation for Rogocekib, a CLK Inhibitor
- Notice of Receipt of Grant
- Non-consolidated Financial Results for the Nine Months Ended May 31 2026 [Japanese GAAP]
Later from Chordia Therapeutics
- Non-consolidated Financial Results for the Fiscal Year Ended August 31, 2026 [Japanese GAAP]
- Fiscal year ended August 2026 Financial Results Presentation
- Announcement Regarding the Reduction of Capital Reserve and Appropriation of Surplus
Follow Chordia Therapeutics into a list and get an email when it puts out news.
Follow Chordia Therapeutics